VRTX Stock Analysis: Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least
- Latest close
- $522.81
- 20-day change
- -4.54%
- Trend state
- LEAN BULL
- Classification
- Healthcare · Biotechnology
Market context
Vertex Pharmaceuticals Inc moved -4.54% over the latest 20-session window. BullRecon currently classifies the broader setup as LEAN BULL.
Latest report
The latest cached company filing period (FY2025 · $12B revenue · $4B net income) is used alongside annual and quarterly history. Values remain tied to their reported period.
Six-dimension read
Profitability is currently the strongest dimension at 5.9/6, while Value is the lowest at 3.3/6. Scores are comparative research signals, not forecasts.